Obexelimab almost completely prevented new inflammatory lesions visible on brain scans of adults with relapsing MS, per trial data.
Learn more about whether Biogen Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Clinical Trials Arena on MSN
Zenas’ bifunctional mAb scores at Phase II in relapsing MS
During the Phase II MoonStone study (NCT06564311), the bifunctional monoclonal antibody (mAb) met its primary endpoint, ...
Clinical Trials Arena on MSN
Multiple sclerosis: three trials to watch
"Multiple sclerosis: three trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback